Polyvation,
Your medicine to innovate

Polyvation Your medicine to innovate

Exclusive License Agreement with Allergan

InnoCore Pharmaceuticals, a polymer technology subsidiary of PolyVation, is excited to announce that it has signed an exclusive License and Collaboration Agreement with Allergan, Inc. (NYSE: AGN), a multi-specialty health care company headquartered in Irvine, California.

Under the agreement, the companies will expand their existing collaboration and jointly continue to develop long-acting ocular drug delivery products for the treatment of ophthalmic diseases. Utilizing its patented SynBiosys™ polymeric drug delivery platform, InnoCore will formulate Allergan's proprietary drugs into pharmaceutical products expected to be capable of sustained release for many months following a single ocular injection. The SynBiosys™ drug delivery platform is based on novel biodegradable multi-block co-polymers with unique molecular architectures that allow precise and site-specific delivery of drugs for predetermined periods of time, ranging from weeks to many months.

Jan Hendriks, Chief Executive Officer of InnoCore Pharmaceuticals commented: "We are very excited that we have expanded this important partnership with Allergan, a company that is widely recognized as a leading company in the development of controlled release ophthalmology medicines. Expanding our partnership with Allergan is a great opportunity for us to further grow InnoCore in line with our ambitions."

More information on InnoCore and SynBiosys™ you will find at www.innocorepharma.com.